AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32299118 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care treatment in Dachau
Number of subjects: 10663
Study 32299390 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD Disk
Number of subjects: 400
Study 32299390 — intervention group
Group type: COMPARATOR
Intervention: IBD-DI
Number of subjects: 400
Study 32299390 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA (Physician Global Assessment)
Number of subjects: 400
Study 32299390 — intervention group
Group type: EXPERIMENTAL
Intervention: PtGA (Patient Global Assessment)
Number of subjects: 400
Study 32299390 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD Disk psychometric criteria
Number of subjects: 400
Study 32299401 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition Readiness and Appropriateness Measure (TRAM)
Number of subjects: 0
Study 32299401 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition Related Outcome Measure (TROM)
Number of subjects: 0
Study 32299420 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Talk Intervention (FTI)
Number of subjects: 34
Study 32299778 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 402
Study 32299817 — intervention group
Group type: EXPERIMENTAL
Intervention: CIVO microinjected drugs
Number of subjects: 13
Study 32299865 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure
Number of subjects: 0
Study 32299865 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32300321 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 week of multiple-game exergaming (including single leg exercises, weight shifting, balancing, and standing up)
Number of subjects: 0
Study 32300321 — intervention group
Group type: COMPARATOR
Intervention: 1 week of conventional balance training
Number of subjects: 0
Study 32300475 — intervention group
Group type: EXPERIMENTAL
Intervention: HiBalance
Number of subjects: 13
Study 32300475 — intervention group
Group type: COMPARATOR
Intervention: HiCommunication
Number of subjects: 13
Study 32300671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Ketamine
Number of subjects: 140
Study 32300671 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 140
Study 32300702 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-created intervention developed through service-learning methodology
Number of subjects: 60
Study 32300702 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 60
Study 32300966 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction dose
Number of subjects: 541
Study 32300966 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher propofol doses
Number of subjects: 541
Study 32300966 — intervention group
Group type: EXPERIMENTAL
Intervention: Excess propofol dose
Number of subjects: 541
Study 32301062 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 ml/kg dose of IGIM
Number of subjects: 28
Study 32301063 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest 2 mg/day
Number of subjects: 25000
Study 32301063 — intervention group
Group type: EXPERIMENTAL
Intervention: Other hormonal medications
Number of subjects: 25000
Study 32301063 — intervention group
Group type: COMPARATOR
Intervention: Dienogest 2 mg/day and other hormonal medications
Number of subjects: 25000
Study 32301258 — intervention group
Group type: EXPERIMENTAL
Intervention: tesidolumab + IVIg
Number of subjects: 8
Study 32301258 — intervention group
Group type: COMPARATOR
Intervention: tesidolumab alone
Number of subjects: 8
Study 32301783 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32301981 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss (WL)
Number of subjects: 34
Study 32303155 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 0
Study 32303155 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 0
Study 32303155 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32303189 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior Active Rhinomanometry (AAR)
Number of subjects: 0
Study 32303379 — intervention group
Group type: EXPERIMENTAL
Intervention: QoR-15F scale administered pre-operation and on Postoperative day 1
Number of subjects: 150
Study 32303379 — intervention group
Group type: EXPERIMENTAL
Intervention: QoR-15F scale
Number of subjects: 150
Study 32303514 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate reasons for ED presentation (no urgent treatment required)
Number of subjects: 356
Study 32303514 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms as a reason for ED presentation
Number of subjects: 356
Study 32303514 — intervention group
Group type: EXPERIMENTAL
Intervention: General fear or anxiety as a reason for ED presentation
Number of subjects: 356
Study 32303514 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior medical advice as a reason for ED presentation
Number of subjects: 356
Study 32303514 — intervention group
Group type: EXPERIMENTAL
Intervention: History of congestive heart failure
Number of subjects: 356
Study 32303514 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-related concerns for ED presentation
Number of subjects: 356
Study 32303514 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for alternatives to ED care
Number of subjects: 356
Study 32303612 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP treatment
Number of subjects: 0
Study 32303612 — intervention group
Group type: COMPARATOR
Intervention: High serum CRP levels
Number of subjects: 0
Study 32303619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 57
Study 32303743 — intervention group
Group type: COMPARATOR
Intervention: Eucaloric diet (CON; n = 11)
Number of subjects: 20
Study 32303743 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat overfeeding diet (HFD; n = 9; 50% excess energy as fat)
Number of subjects: 20
Study 32303913 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined retinal electromagnetic stimulation and subtenon platelet-rich plasma (group 1)
Number of subjects: 60
Study 32303913 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtenon platelet-rich plasma only (group 2)
Number of subjects: 60
Study 32303913 — intervention group
Group type: COMPARATOR
Intervention: Natural course (control group 3)
Number of subjects: 60
Study 32303994 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) as first-line biologic agent
Number of subjects: 1454
Study 32303994 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) as second-line biologic agent
Number of subjects: 1454
Study 32303994 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) as at least third-line biologic agent
Number of subjects: 1454
Study 32303994 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) in PsA as first-line biologic agent
Number of subjects: 1454
Study 32303994 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) in PsA as second-line biologic agent
Number of subjects: 1454
Study 32303994 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) in PsA as at least third-line biologic agent
Number of subjects: 1454
Study 32303994 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) in AS as first-line biologic agent
Number of subjects: 1454
Study 32303994 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) in AS as second-line biologic agent
Number of subjects: 1454
Study 32303994 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GLM) in AS as at least third-line biologic agent
Number of subjects: 1454
Study 32304462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-positive group
Number of subjects: 328
Study 32304462 — intervention group
Group type: COMPARATOR
Intervention: Cocaine-negative group
Number of subjects: 328
Study 32304510 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg extensor (LE) maximal muscle power measured in a Nottingham Power Rig
Number of subjects: 40
Study 32304510 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extensor (KE) peak isometric strength measured with a handheld dynamometer
Number of subjects: 40
Study 32304510 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-m walk test
Number of subjects: 40
Study 32304510 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-second chair-stand test
Number of subjects: 40
Study 32304510 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-step stair climb test
Number of subjects: 40
Study 32304640 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 0
Study 32304847 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta/Beta Neurofeedback (NFB)
Number of subjects: 67
Study 32304847 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (MPH)
Number of subjects: 67
Study 32304847 — intervention group
Group type: COMPARATOR
Intervention: Physical Activity (PA)
Number of subjects: 67
Study 32304877 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologics (n=557); 51% anti-immunoglobulin E, 48% anti-IL-5/IL-5Rα; 76% of initiations from May 2018 were anti-IL-5/IL-5Rα
Number of subjects: 796
Study 32304877 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance systemic corticosteroids (mSCS); median prednisone-equivalent daily dose of 10 mg
Number of subjects: 796
Study 32304877 — intervention group
Group type: COMPARATOR
Intervention: Patients of hospital clinics, sites with fewer nonphysician staff, and with a recorded concurrent chronic obstructive pulmonary disease diagnosis
Number of subjects: 796
Study 32305010 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 400 mg every 6 weeks (Q6W)
Number of subjects: 2993
Study 32305010 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab 200 mg every 3 weeks (Q3W)
Number of subjects: 2993
Study 32305010 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab 2 mg/kg every 3 weeks (Q3W)
Number of subjects: 2993
Study 32305010 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab 10 mg/kg every 2 weeks (Q2W)
Number of subjects: 2993
Study 32305219 — intervention group
Group type: EXPERIMENTAL
Intervention: VA-ECMO for TAAD
Number of subjects: 62
Study 32306096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2 mg/0.05 mL monthly for three injections followed by every 8 weeks
Number of subjects: 20
Study 32306273 — intervention group
Group type: EXPERIMENTAL
Intervention: Time interval > 57 days after NRCT
Number of subjects: 167
Study 32306273 — intervention group
Group type: COMPARATOR
Intervention: Time intervals 0-42 days and 43-56 days after NRCT
Number of subjects: 167
Study 32306296 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (EQW)
Number of subjects: 954
Study 32306296 — intervention group
Group type: COMPARATOR
Intervention: Placebo/non-glucagon-like peptide-1 receptor agonist comparator (sitagliptin, metformin, pioglitazone, dapagliflozin, insulin)
Number of subjects: 954
Study 32306413 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral sleep interventions (BSIs)
Number of subjects: 40
Study 32306413 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding near bedtime or during the night
Number of subjects: 40
Study 32306413 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-sleeping
Number of subjects: 40
Study 32306413 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental sleep knowledge
Number of subjects: 40
Study 32306413 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep characteristics measured by actigraphy
Number of subjects: 40
Study 32306809 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive reserve ratio (RRR)
Number of subjects: 1245
Study 32306809 — intervention group
Group type: COMPARATOR
Intervention: Fractional flow reserve (FFR)
Number of subjects: 1245
Study 32306809 — intervention group
Group type: COMPARATOR
Intervention: Coronary flow reserve (CFR)
Number of subjects: 1245
Study 32306965 — intervention group
Group type: EXPERIMENTAL
Intervention: WHOQOL-BREF
Number of subjects: 254
Study 32307017 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate SBRT (37.5Gy, 5 fractions of 7.5Gy) guided by prostate gold fiducial markers
Number of subjects: 8
Study 32307193 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-3 eggs/week
Number of subjects: 18914
Study 32307193 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-7 eggs/week
Number of subjects: 18914
Study 32307193 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-2 eggs/day
Number of subjects: 18914
Study 32307193 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥2 eggs/day
Number of subjects: 18914
Study 32307193 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol from eggs
Number of subjects: 18914
Study 32307193 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol from non-egg sources
Number of subjects: 18914
Study 32307193 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting 50 g/d egg for dairy products
Number of subjects: 18914
Study 32307193 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting 50 g/d egg for nuts/legumes
Number of subjects: 18914
Study 32307193 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting 50 g/d egg for red meat
Number of subjects: 18914
Study 32307279 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose inactivated hepatitis-A virus (HAV) vaccine
Number of subjects: 259
Study 32307279 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose live attenuated varicella zoster virus (VZV) vaccine
Number of subjects: 259
Study 32307279 — intervention group
Group type: COMPARATOR
Intervention: Single dose VZV vaccine
Number of subjects: 259
Study 32307443 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT combined with Family History Questionnaire (FHQ)
Number of subjects: 5979
Study 32307443 — intervention group
Group type: COMPARATOR
Intervention: FIT only
Number of subjects: 5979
Study 32307533 — intervention group
Group type: EXPERIMENTAL
Intervention: Dawn simulation light
Number of subjects: 23
Study 32307594 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analysis
Number of subjects: 0
Study 32307692 — intervention group
Group type: EXPERIMENTAL
Intervention: OCD patients
Number of subjects: 21
Study 32307692 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 21
Study 32308367 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan
Number of subjects: 566
Study 32308505 — intervention group
Group type: EXPERIMENTAL
Intervention: FTD/TPI (35 mg/m²)
Number of subjects: 15
Study 32308680 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin administration
Number of subjects: 6
Study 32308987 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT/sMF during training and detraining (PBMT/sMF + PBMT/sMF)
Number of subjects: 60
Study 32308987 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT/sMF during training and placebo during detraining (PBMT/sMF + Placebo)
Number of subjects: 60
Study 32308987 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo during training and PBMT/sMF during detraining (Placebo+PBMT/sMF)
Number of subjects: 60
Study 32308987 — intervention group
Group type: COMPARATOR
Intervention: Placebo during training and detraining (Placebo+Placebo)
Number of subjects: 60
Study 32309284 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Servo-Ventilation
Number of subjects: 0
Study 32309426 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC+CHO (300 mL of oral carbohydrate administered 2 hours before surgery)
Number of subjects: 77
Study 32309426 — intervention group
Group type: COMPARATOR
Intervention: NAC (two cycles of chemotherapy followed by surgery)
Number of subjects: 77
Study 32309426 — intervention group
Group type: COMPARATOR
Intervention: Non-NAC (surgery alone)
Number of subjects: 77
Study 32309637 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (BUP)
Number of subjects: 0
Study 32309673 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Oncology care plus Palliative Care (PC)
Number of subjects: 97
Study 32309673 — intervention group
Group type: COMPARATOR
Intervention: Standard Oncology care
Number of subjects: 97
Study 32310027 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2240
Study 32310027 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 2240
Study 32310137 — intervention group
Group type: EXPERIMENTAL
Intervention: MacPLUS FS (McMaster Premium LiteratUre Service Federated Search)
Number of subjects: 908
Study 32310137 — intervention group
Group type: EXPERIMENTAL
Intervention: MacPLUS FS
Number of subjects: 908
Study 32310146 — intervention group
Group type: EXPERIMENTAL
Intervention: AGE-ON tablet training program
Number of subjects: 32
Study 32310294 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab treatment
Number of subjects: 53
Study 32310699 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine treatment with metoclopramide coadministration
Number of subjects: 0
Study 32310699 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine treatment without metoclopramide
Number of subjects: 0
Study 32310699 — intervention group
Group type: COMPARATOR
Intervention: Control group (no morphine treatment)
Number of subjects: 0
Study 32310851 — intervention group
Group type: EXPERIMENTAL
Intervention: Predilation
Number of subjects: 17084
Study 32310851 — intervention group
Group type: COMPARATOR
Intervention: Post-dilation
Number of subjects: 17084
Study 32310851 — intervention group
Group type: COMPARATOR
Intervention: Moderate/severe CAC presence
Number of subjects: 17084
Study 32311022 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive health checks with attributes: assess, advice, agree, assist, arrange
Number of subjects: 148
Study 32311037 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 43
Study 32311037 — intervention group
Group type: COMPARATOR
Intervention: Bariatric surgery
Number of subjects: 43
Study 32311037 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 43
Study 32311926 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Diet (HD) - increase fruit and vegetable intake to 5 servings per day (equivalent to 500g)
Number of subjects: 0
Study 32311926 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Diet plus Physical Activity (HD-PA) - same dietary intervention as HD plus engage in moderate-to-vigorous physical activities for at least 150 minutes per week
Number of subjects: 0
Study 32311926 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 0
Study 32311926 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Diet (HD)
Number of subjects: 0
Study 32311926 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Diet plus Physical Activity (HD-PA)
Number of subjects: 0
Study 32311940 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tACS intervention (77.5-Hz, 15-mA, 40-minute sessions for 4 weeks)
Number of subjects: 70
Study 32311940 — intervention group
Group type: COMPARATOR
Intervention: Sham tACS (placebo control)
Number of subjects: 70
Study 32311940 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tACS intervention
Number of subjects: 70
Study 32312243 — intervention group
Group type: EXPERIMENTAL
Intervention: Connected behavioral condition
Number of subjects: 148
Study 32312243 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 148
Study 32312249 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (ISB)
Number of subjects: 50
Study 32312249 — intervention group
Group type: COMPARATOR
Intervention: Control (no regional block)
Number of subjects: 50
Study 32312299 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate transfusion strategy
Number of subjects: 177
Study 32312783 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperaquine
Number of subjects: 1000
Study 32312893 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (multi-kinase inhibitor)
Number of subjects: 13
Study 32312891 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib monotherapy
Number of subjects: 63
Study 32312891 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib in combination with Fulvestrant
Number of subjects: 63
Study 32312974 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic saturated fatty acids (SFA)
Number of subjects: 0
Study 32312974 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono- and polyunsaturated fatty acids
Number of subjects: 0
Study 32313451 — intervention group
Group type: EXPERIMENTAL
Intervention: Latiglutenase (900 mg)
Number of subjects: 398
Study 32313451 — intervention group
Group type: COMPARATOR
Intervention: Latiglutenase
Number of subjects: 398
Study 32313553 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-drink SPMC oral solution
Number of subjects: 0
Study 32313731 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat shock protein peptide complex-96 (HSPPC-96) vaccine
Number of subjects: 0
Study 32314262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of gastric content before anesthesia induction
Number of subjects: 138
Study 32314268 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib (0.2-0.8 mg/kg intravenously) intermittently or weekly; Refametinib (30-50 mg twice daily orally) continuously or 4 days on/3 days off.
Number of subjects: 64
Study 32314956 — intervention group
Group type: EXPERIMENTAL
Intervention: Task engagement with multimodal network analyses integrating functional and molecular neuroimaging.
Number of subjects: 0
Study 32314956 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased cognitive load above initial task engagement.
Number of subjects: 0
Study 32314972 — intervention group
Group type: EXPERIMENTAL
Intervention: New algorithm based on the Quantra system
Number of subjects: 20
Study 32314972 — intervention group
Group type: COMPARATOR
Intervention: Existing algorithm based on the ROTEM/Multiplate system
Number of subjects: 20
Study 32314973 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Auditory Feedback (DAF) + real transcranial direct current stimulation (tDCS)
Number of subjects: 30
Study 32314973 — intervention group
Group type: COMPARATOR
Intervention: Delayed Auditory Feedback (DAF) + sham transcranial direct current stimulation (tDCS)
Number of subjects: 30